erlotinib hydrochloride has been researched along with losartan in 1 studies
Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (losartan) | Trials (losartan) | Recent Studies (post-2010) (losartan) |
---|---|---|---|---|---|
4,353 | 786 | 3,033 | 7,231 | 1,245 | 2,118 |
Protein | Taxonomy | erlotinib hydrochloride (IC50) | losartan (IC50) |
---|---|---|---|
Bile salt export pump | Homo sapiens (human) | 9.01 | |
Cytochrome P450 2C9 | Homo sapiens (human) | 2.882 | |
Angiotensin-converting enzyme | Homo sapiens (human) | 0.019 | |
Atrial natriuretic peptide receptor 3 | Homo sapiens (human) | 0.0018 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.019 | |
Type-1A angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0247 | |
Type-1B angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0234 | |
Adenosine receptor A2a | Rattus norvegicus (Norway rat) | 0.0032 | |
Type-1 angiotensin II receptor | Homo sapiens (human) | 0.047 | |
Type-1 angiotensin II receptor | Oryctolagus cuniculus (rabbit) | 0.025 | |
Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0118 | |
Type-2 angiotensin II receptor | Homo sapiens (human) | 0.019 | |
Platelet glycoprotein VI | Homo sapiens (human) | 4 | |
Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 1.1481 | |
Type-1 angiotensin II receptor | Cavia porcellus (domestic guinea pig) | 0.018 | |
Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 0.2884 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Böhmer, FD; Kirches, E; Mawrin, C; Pachow, D; Petermann, A; Wallesch, M; Wilisch-Neumann, A | 1 |
1 other study(ies) available for erlotinib hydrochloride and losartan
Article | Year |
---|---|
Re-evaluation of cytostatic therapies for meningiomas in vitro.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Hydroxyurea; Losartan; Meningeal Neoplasms; Meningioma; Metformin; Mifepristone; Neurofibromin 2; Promoter Regions, Genetic; Quinazolines; Radiation Tolerance; Tamoxifen; Temozolomide; Tumor Suppressor Proteins; Verapamil | 2014 |